Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report

BACKGROUND: Rearranged during transfection (RET) is one of the rare driver genes of non-small-cell lung cancer (NSCLC), having a gene fusion incidence of 1–2% in NSCLC. Before the emergence of specific RET inhibitors, multikinase inhibitors such as cabozantinib and vandetanib were tried for RET fusi...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Yan, Li, Lulu, Wang, Huan, Chen, Xiaofang, Yue, Yali, Wang, Meiqing, Meng, Lingru, Li, Bafei, Li, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096366/
https://www.ncbi.nlm.nih.gov/pubmed/35571397
http://dx.doi.org/10.21037/atm-22-1237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096366/
https://www.ncbi.nlm.nih.gov/pubmed/35571397
http://dx.doi.org/10.21037/atm-22-1237

Ejemplares similares